Log in

NASDAQ:MNTAMomenta Pharmaceuticals Stock Price, Forecast & News

+0.59 (+1.82 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $32.99
50-Day Range
MA: $33.65
52-Week Range
Now: $32.99
Volume869,317 shs
Average Volume868,658 shs
Market Capitalization$3.88 billion
P/E RatioN/A
Dividend YieldN/A
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Read More
Momenta Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:MNTA



Sales & Book Value

Annual Sales$23.87 million
Book Value$4.59 per share


Net Income$-290,050,000.00
Net Margins-994.16%


Market Cap$3.88 billion
Next Earnings Date8/10/2020 (Confirmed)
+0.59 (+1.82 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MNTA News and Ratings via Email

Sign-up to receive the latest news and ratings for MNTA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Momenta Pharmaceuticals (NASDAQ:MNTA) Frequently Asked Questions

How has Momenta Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Momenta Pharmaceuticals' stock was trading at $26.39 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MNTA stock has increased by 25.0% and is now trading at $32.99.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Momenta Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Momenta Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Momenta Pharmaceuticals

When is Momenta Pharmaceuticals' next earnings date?

Momenta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Momenta Pharmaceuticals

How were Momenta Pharmaceuticals' earnings last quarter?

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) released its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.34) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.48) by $0.14. The biotechnology company had revenue of $8.89 million for the quarter, compared to analyst estimates of $4.08 million. Momenta Pharmaceuticals had a negative return on equity of 80.37% and a negative net margin of 994.16%.
View Momenta Pharmaceuticals' earnings history

What price target have analysts set for MNTA?

10 brokers have issued twelve-month target prices for Momenta Pharmaceuticals' stock. Their forecasts range from $29.00 to $57.00. On average, they expect Momenta Pharmaceuticals' share price to reach $43.44 in the next twelve months. This suggests a possible upside of 31.7% from the stock's current price.
View analysts' price targets for Momenta Pharmaceuticals

Has Momenta Pharmaceuticals been receiving favorable news coverage?

News articles about MNTA stock have been trending negative on Monday, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Momenta Pharmaceuticals earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Momenta Pharmaceuticals

Who are some of Momenta Pharmaceuticals' key competitors?

What other stocks do shareholders of Momenta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Momenta Pharmaceuticals investors own include Exelixis (EXEL), Amicus Therapeutics (FOLD), Novavax (NVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), ACADIA Pharmaceuticals (ACAD), Halozyme Therapeutics (HALO), NVIDIA (NVDA), Omeros (OMER) and Progenics Pharmaceuticals (PGNX).

Who are Momenta Pharmaceuticals' key executives?

Momenta Pharmaceuticals' management team includes the following people:
  • Mr. Craig A. Wheeler, Pres, CEO & Exec. Director (Age 59)
  • Dr. Ganesh Venkataraman Kaundinya, Co-Founder & Consultant (Age 52)
  • Dr. Santiago Arroyo, Chief Medical Officer & Sr. VP of Devel. (Age 59)
  • Mr. Bruce A. Leicher, Consultant (Age 63)
  • Mr. Scott M. Storer, Consultant

What is Momenta Pharmaceuticals' stock symbol?

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

Who are Momenta Pharmaceuticals' major shareholders?

Momenta Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Viking Global Investors LP (0.80%), Principal Financial Group Inc. (0.78%), Jennison Associates LLC (0.52%), Peregrine Capital Management LLC (0.35%), Candriam Luxembourg S.C.A. (0.35%) and Swiss National Bank (0.21%). Company insiders that own Momenta Pharmaceuticals stock include Agnieszka Cieplinska, Alejandra Carvajal, Anthony M Manning, Bruce Downey, Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Georges Gemayel, Ian Fier, Jo Ann Beltramello, Jose-Carlos Gutierrez-Ramos, Michelle Robertson, Santiago Arroyo, Steven C Gilman and Young Kwon.
View institutional ownership trends for Momenta Pharmaceuticals

Which institutional investors are selling Momenta Pharmaceuticals stock?

MNTA stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, UBS Group AG, Russell Investments Group Ltd., Virtus ETF Advisers LLC, Trexquant Investment LP, Fisher Asset Management LLC, SG Americas Securities LLC, and First Trust Advisors LP. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Agnieszka Cieplinska, Alejandra Carvajal, Anthony M Manning, Craig A Wheeler, Elizabeth Stoner, Georges Gemayel, Ian Fier, Jo Ann Beltramello, Jose-Carlos Gutierrez-Ramos, Michelle Robertson, Santiago Arroyo, Steven C Gilman, and Young Kwon.
View insider buying and selling activity for Momenta Pharmaceuticals

Which institutional investors are buying Momenta Pharmaceuticals stock?

MNTA stock was purchased by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Candriam Luxembourg S.C.A., Asymmetry Capital Management L.P., New York State Teachers Retirement System, Principal Financial Group Inc., Rafferty Asset Management LLC, Handelsinvest Investeringsforvaltning, and Swiss National Bank.
View insider buying and selling activity for Momenta Pharmaceuticals

How do I buy shares of Momenta Pharmaceuticals?

Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Momenta Pharmaceuticals' stock price today?

One share of MNTA stock can currently be purchased for approximately $32.99.

How big of a company is Momenta Pharmaceuticals?

Momenta Pharmaceuticals has a market capitalization of $3.88 billion and generates $23.87 million in revenue each year. The biotechnology company earns $-290,050,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis. Momenta Pharmaceuticals employs 131 workers across the globe.

What is Momenta Pharmaceuticals' official website?

The official website for Momenta Pharmaceuticals is www.momentapharma.com.

How can I contact Momenta Pharmaceuticals?

Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.